Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HHH NASDAQ:HST NASDAQ:REG NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHHHHoward Hughes$63.38+2.6%$65.47$61.01▼$91.07$3.68B1.15455,525 shs361,295 shsHSTHost Hotels & Resorts$21.31+2.2%$19.81$14.37▼$21.55$14.34B1.17.84 million shs7.20 million shsREGRegency Centers$78.89+0.2%$77.88$66.86▼$81.66$14.42B0.821.50 million shs1.26 million shsTSHATaysha Gene Therapies$6.94+4.5%$4.99$1.85▼$6.95$1.91B1.252.78 million shs2.24 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHHHHoward Hughes0.00%-2.41%-0.61%-22.07%-7.60%HSTHost Hotels & Resorts0.00%+1.27%+10.48%+12.06%+42.97%REGRegency Centers0.00%-1.63%+2.17%+8.50%+7.70%TSHATaysha Gene Therapies0.00%-2.01%+44.85%+34.11%+145.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHHHHoward Hughes$63.38+2.6%$65.47$61.01▼$91.07$3.68B1.15455,525 shs361,295 shsHSTHost Hotels & Resorts$21.31+2.2%$19.81$14.37▼$21.55$14.34B1.17.84 million shs7.20 million shsREGRegency Centers$78.89+0.2%$77.88$66.86▼$81.66$14.42B0.821.50 million shs1.26 million shsTSHATaysha Gene Therapies$6.94+4.5%$4.99$1.85▼$6.95$1.91B1.252.78 million shs2.24 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHHHHoward Hughes0.00%-2.41%-0.61%-22.07%-7.60%HSTHost Hotels & Resorts0.00%+1.27%+10.48%+12.06%+42.97%REGRegency Centers0.00%-1.63%+2.17%+8.50%+7.70%TSHATaysha Gene Therapies0.00%-2.01%+44.85%+34.11%+145.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHHHHoward Hughes 2.00Hold$83.3331.49% UpsideHSTHost Hotels & Resorts 2.67Moderate Buy$21.380.35% UpsideREGRegency Centers 2.53Moderate Buy$81.002.67% UpsideTSHATaysha Gene Therapies 3.00Buy$11.6467.67% UpsideCurrent Analyst Ratings BreakdownLatest HHH, TSHA, HST, and REG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026REGRegency Centers CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$76.00 ➝ $82.005/1/2026REGRegency Centers EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$80.004/24/2026HHHHoward Hughes Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/22/2026HSTHost Hotels & Resorts Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $23.004/21/2026HSTHost Hotels & Resorts JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$21.00 ➝ $22.004/21/2026REGRegency Centers Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$85.00 ➝ $88.004/10/2026HSTHost Hotels & Resorts UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$18.00 ➝ $20.004/10/2026HSTHost Hotels & Resorts Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$18.00 ➝ $20.004/7/2026HSTHost Hotels & Resorts BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$19.00 ➝ $20.004/6/2026HHHHoward Hughes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/6/2026TSHATaysha Gene Therapies Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $17.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHHHHoward Hughes$1.47B2.56$6.37 per share9.95$49.69 per share1.28HSTHost Hotels & Resorts$6.11B2.40$2.33 per share9.13$9.54 per share2.23REGRegency Centers$1.55B9.30$5.07 per share15.57$37.91 per share2.08TSHATaysha Gene Therapies$9.77M204.11N/AN/A$0.90 per share7.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHHHHoward Hughes$131.88M$2.1130.0418.59N/A8.40%5.54%1.68%N/AHSTHost Hotels & Resorts$765M$1.1019.3710.152.4012.51%11.54%5.89%5/6/2026 (Estimated)REGRegency Centers$527.46M$2.9027.2015.563.3834.47%7.99%4.22%N/ATSHATaysha Gene Therapies-$109M-$0.34N/AN/AN/AN/A-56.64%-38.53%5/6/2026 (Estimated)Latest HHH, TSHA, HST, and REG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026HSTHost Hotels & Resorts$0.3575N/AN/AN/A$1.59 billionN/A5/6/2026Q1 2026TSHATaysha Gene Therapies-$0.10N/AN/AN/A$0.76 millionN/A3/19/2026Q4 2025TSHATaysha Gene Therapies-$0.11-$0.08+$0.03-$0.08$1.89 million$5.49 million2/19/2026Q4 2025HHHHoward Hughes$0.31$0.10-$0.21$0.10N/A$624.45 million2/18/2026Q4 2025HSTHost Hotels & Resorts$0.47$0.20-$0.27$0.20$1.49 billion$1.60 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHHHHoward HughesN/AN/AN/AN/AN/AHSTHost Hotels & Resorts$0.803.75%+36.56%72.73%2 YearsREGRegency Centers$3.023.83%+3.82%104.14%5 YearsTSHATaysha Gene TherapiesN/AN/AN/AN/AN/ALatest HHH, TSHA, HST, and REG DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/18/2026HSTHost Hotels & Resortsquarterly$0.204.18%3/31/20263/31/20264/15/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHHHHoward Hughes1.731.191.19HSTHost Hotels & Resorts0.772.592.59REGRegency Centers0.722.061.05TSHATaysha Gene Therapies0.2012.2312.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHHHHoward Hughes93.83%HSTHost Hotels & Resorts98.52%REGRegency Centers96.07%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipHHHHoward Hughes48.00%HSTHost Hotels & Resorts1.50%REGRegency Centers1.00%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHHHHoward Hughes60859.62 million31.01 millionOptionableHSTHost Hotels & Resorts160687.33 million677.02 millionOptionableREGRegency Centers440183.08 million181.25 millionOptionableTSHATaysha Gene Therapies180287.34 million276.48 millionOptionableHHH, TSHA, HST, and REG HeadlinesRecent News About These CompaniesTaysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month High - Here's What HappenedMay 5 at 3:39 PM | marketbeat.comTaysha Gene Therapies (TSHA) to Release Earnings on WednesdayMay 2 at 2:41 AM | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comTaysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6April 29, 2026 | globenewswire.comHas Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?April 28, 2026 | finance.yahoo.comTaysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual MeetingApril 27, 2026 | quiverquant.comQTaysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual MeetingApril 27, 2026 | globenewswire.comTaysha Gene Therapies, Inc. ($TSHA) CEO and Director 2025 Pay RevealedApril 22, 2026 | quiverquant.comQTaysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month High - Should You Buy?April 22, 2026 | marketbeat.comTaysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago LevelsApril 22, 2026 | insidermonkey.comTaysha Gene Therapies Sees Unusually High Options Volume (NASDAQ:TSHA)April 16, 2026 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Sets New 12-Month High - Still a Buy?April 16, 2026 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Up 9% - Should You Buy?April 15, 2026 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by BrokeragesApril 15, 2026 | marketbeat.comThis is why Taysha Gene Therapies, Inc. (TSHA) is one of the best healthcare penny stocks to buyApril 14, 2026 | msn.comTaysha Gene Therapies (NASDAQ:TSHA) Insider Sells $892,000.00 in StockApril 14, 2026 | insidertrades.comTaysha Gene Therapies (NASDAQ:TSHA) Insider Sukumar Nagendran Sells 200,000 SharesApril 13, 2026 | marketbeat.comAberdeen Group plc Purchases Shares of 1,021,063 Taysha Gene Therapies, Inc. $TSHAApril 9, 2026 | marketbeat.com5 Best Multibagger Penny Stocks to Invest InApril 6, 2026 | insidermonkey.comTaysha Gene Therapies, Inc. (TSHA) making progress on crucial Rett syndrome treatmentApril 6, 2026 | msn.comTaysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome TreatmentApril 6, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHHH, TSHA, HST, and REG Company DescriptionsHoward Hughes NYSE:HHH$63.38 +1.64 (+2.65%) Closing price 03:59 PM EasternExtended Trading$62.45 -0.92 (-1.46%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.Host Hotels & Resorts NASDAQ:HST$21.31 +0.45 (+2.16%) Closing price 04:00 PM EasternExtended Trading$21.22 -0.09 (-0.45%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Host Hotels & Resorts, Inc. is a real estate investment trust, which engages in the management of luxury and upper-upscale hotels. It operates through the following geographical segments: United States, Brazil, and Canada. The company was founded in 1927 and is headquartered in Bethesda, MD.Regency Centers NASDAQ:REG$78.89 +0.14 (+0.18%) Closing price 04:00 PM EasternExtended Trading$78.88 -0.01 (-0.01%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regency Centers is a preeminent national owner, operator, and developer of shopping centers located in suburban trade areas with compelling demographics. Our portfolio includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers. Operating as a fully integrated real estate company, Regency Centers is a qualified real estate investment trust (REIT) that is self-administered, self-managed, and an S&P 500 Index member.Taysha Gene Therapies NASDAQ:TSHA$6.94 +0.30 (+4.52%) Closing price 04:00 PM EasternExtended Trading$6.89 -0.05 (-0.75%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
